

Benzodiazepine Tolerance at GABAergic Synapses on Hippocampal CA1 Pyramidal Cells

XU J. ZENG AND ELIZABETH I. TIETZ*

Department of Pharmacology, Medical College of Ohio, Toledo, Ohio 43614-5804

KEY WORDS flurazepam; dependence; interneuron; release; hippocampus; IPSCs

ABSTRACT Modulation of GABA function following 1 week oral administration of flurazepam (FZP) was investigated in chloride-loaded, rat hippocampal CA1 pyramidal neurons. Rats were sacrificed 2 or 7 days after ending drug treatment, when anticonvulsant tolerance was present or absent *in vivo*, respectively. Spontaneous (s)IPSCs and miniature (m)IPSCs were recorded using whole-cell voltage-clamp techniques. s/mIPSCs were bicuculline-sensitive, voltage-dependent, and reversed their polarity at 0 mV, the predicted E_{Cl^-} . Comparisons of s/mIPSCs between FZP-treated and control groups were made at $V_h = -90, -70, \text{ and } -50$ mV. The frequency of sIPSCs, but not mIPSCs, was significantly decreased in FZP-treated neurons 2 days, but not 7 days, after FZP treatment, suggesting a decrease in interneuron activity. These conclusions were supported by the negative findings of additional studies of [^3H]GABA release from hippocampal slices and [^3H]GABA uptake from hippocampal synaptosomes. The lack of change in the paired-pulse depression of GABA_B-mediated IPSPs suggested that autoreceptor function was also not impaired following chronic FZP treatment. A large reduction in both sIPSC and mIPSC amplitude (60%) in FZP-treated neurons, the absence of mIPSCs in one-third of FZP-treated cells, and a measurable reduction in synaptic and unitary conductance confirmed that postsynaptic GABA_A receptor function was profoundly impaired in FZP-treated CA1 neurons. Zolpidem, an $\alpha 1$ -selective benzodiazepine receptor ligand, enhanced mIPSC amplitude and decay, but its ability to prolong mIPSC decay was reduced in FZP-treated neurons. Several pre- and post-synaptic changes at GABAergic synapses on CA1 pyramidal cells might be related to the decreased tonic GABA inhibition in FZP-treated CA1 neurons associated with the expression of benzodiazepine anticonvulsant tolerance. **Synapse 31:263-277, 1999.** © 1999 Wiley-Liss, Inc.

INTRODUCTION

Benzodiazepines exert their therapeutically useful anticonvulsant actions by potentiating inhibitory neurotransmission (Eghbali et al., 1997; Rogers et al., 1994; Study and Barker, 1981) at the GABA_A receptor, a pentameric protein constituting a chloride (Cl⁻) channel formed from a combination of subunits with multiple variants ($\alpha 1-6, \beta 1-4, \gamma 1-3, \delta 1$ or $\epsilon 1$) (Davies et al., 1997; Delorey and Olsen, 1992; Macdonald and Olsen, 1994). Repeated benzodiazepine administration results in anticonvulsant tolerance (for review see Hutchinson et al., 1996). Findings of *in vivo* electrophysiological studies and [$^{36}\text{Cl}^-$] flux studies in tolerant animals showed reductions in GABA and benzodiazepine agonist actions. Studies measuring the affinity and number of GABA and benzodiazepine binding sites were inconclusive despite consistent reductions in allosteric

coupling between the two binding sites (for reviews see Barnes, 1996; Gallager et al., 1991; Hutchinson et al., 1996). The modulation of expression of several GABA_A receptor subunit mRNAs (Heninger et al., 1990; Holt et al., 1996; Impagnatiello et al., 1996; Kang and Miller, 1991; Tietz et al., 1994; Zhao et al., 1994) implied a change in the subunit composition of GABA_A receptors. Notwithstanding such findings, the definitive changes that occur at GABAergic synapses during sustained allosteric activation of GABA_A receptors and their functional consequences remain unknown.

Contract grant sponsor: National Institutes of Health; Contract grant numbers: RO1-DA04075, KO2-DA00180.

*Correspondence to: Elizabeth I. Tietz, Ph.D., Department of Pharmacology, Medical College of Ohio, 3035 Arlington Ave., Toledo, OH 43614-5804. E-mail: etietz@mco.edu

Received 10 March 1998; Accepted 13 July 1998.

A series of electrophysiological studies in the CA1 region of in vitro hippocampal slices derived from FZP tolerant rats led us to hypothesize that presynaptic, as well as postsynaptic, mechanisms may contribute to reduced GABAergic inhibition (Xie and Tietz, 1991, 1992; Zeng and Tietz, 1994, 1997; Zeng et al., 1995). A major focus of the present experiments was to further investigate GABAergic inhibitory function in CA1 pyramidal cells in hippocampal slices derived from rats sacrificed at two time points after one week oral flurazepam administration when tolerance in vivo (Rosenberg et al., 1985) and in vitro (Xie and Tietz, 1992) is near maximal or absent, respectively. The possibility that interneuron excitability was altered was supported by the negative findings of additional biochemical studies of GABA uptake and action-potential independent KCl-evoked GABA release and by studies of presynaptic, GABA_B receptor-mediated, paired-pulse depression. To further evaluate postsynaptic changes at the GABA_A receptor suggested by the reductions in action potential-dependent sIPSC and action potential-independent mIPSCs and in evoked IPSC amplitude (De Koninck and Mody, 1992; Nusser et al., 1997), unitary Cl⁻ channel conductance was estimated from non-stationary fluctuation analyses of mIPSCs. In addition, since in situ hybridization and immunocytochemical studies had suggested that the $\alpha 1$ subunit mRNA and protein were selectively reduced in CA1 pyramidal cells (Chen et al., 1996; Huang et al., 1995; Tietz et al., 1994), in vitro tolerance was investigated in concentration-response studies of the $\alpha 1$ -selective benzodiazepine receptor ligand, zolpidem, on mIPSC kinetics.

MATERIALS AND METHODS

Oral flurazepam administration

Male Sprague-Dawley rats (initial weight 185–225 g) were offered FZP in 0.02% saccharin solution as their only source of drinking water. The concentration of FZP was adjusted daily according to each rat's body weight and fluid consumption (100 mg/kg X 3 days and 150 mg/kg X 4 days). Only rats that consumed a criterion dose of an average ≥ 100 mg/kg/day were accepted for study. Saccharin water was offered 2 days prior to initiating drug treatment and for 2 or 7 days after ending treatment. Pair-handled control rats received saccharin water for the same length of time. The experimenter was not informed the rats' treatment histories until after the data analysis was completed.

Rats receiving 1 week oral FZP treatment show a loss in the ability of benzodiazepines to protect against pentylenetetrazol-induced seizures up to 4, but not 7, days after ending drug treatment (Rosenberg et al., 1985; Rosenberg, 1995). Therefore, FZP-treated and paired-handled control rats were sacrificed 2 or 7 days after 1 week FZP-treatment when benzodiazepine functional tolerance is near-maximal or absent, respectively. Moreover, 1 week FZP-treated rats are tolerant

but not dependent (Tietz and Rosenberg, 1988). The initial brain levels of benzodiazepine metabolites are equivalent to or less than those using other treatment protocols (Gallager et al., 1991; Hutchinson et al., 1996). In addition, FZP and its active metabolites were not detected in the hippocampus 2 days after 1 week FZP administration (Xie and Tietz, 1991). Thus, electrophysiological measurements were not affected by residual benzodiazepine metabolites.

Hippocampal slice preparation

Experiments were carried out in 500 μ m hippocampal slices from FZP-treated and control rats as previously described (Zeng et al., 1995; Zeng and Tietz, 1997). Briefly, rats were decapitated and transverse dorsal hippocampal slices were prepared on a vibratome (Ted Pella, Inc., Redding, CA) in ice-cold pre-gassed (95%O₂/5%CO₂) ACSF containing (in mM) NaCl 120, KCl 5.0, MgSO₄ 1.3, NaH₂PO₄ 1.2, CaCl₂ 2.4, NaHCO₃ 26, D-glucose 10; 288 mOsm, pH 7.3. Slices were stored at room temperature for ≥ 1 hr in gassed ACSF. During recording individual slices were continuously perfused at a constant rate of 1.5 ml/minute with pre-gassed ACSF at room temperature.

Electrophysiological studies

Whole-cell recordings

Tight-seal, whole-cell voltage-clamp recordings were made from CA1 pyramidal neurons. Patch pipettes were pulled from borosilicate capillaries (nonfilamented, 1.5 mm O.D., Sutter Instruments Co., Novato, CA) on a Flaming-Brown electrode puller (P-97, Sutter Instruments Co.) using a two-stage pull to a tip diameter of about 1 μ m (4–7 M Ω). To isolate GABA_A mediated IPSCs, pipettes were filled with a filtered, Cs⁺-containing internal solution containing (in mM): CsCl 130, EGTA 1.0, CaCl₂ 0.5, MgCl₂ 2.0, ATP 2.0, HEPES 10.0, pH adjusted to 7.2. Cells were Cl⁻-loaded to minimize the possible contribution of intracellular Cl⁻ accumulation to the reduction of GABA-mediated inhibition suggested by a shift in the E_{IPSP} in previous experiments in FZP-treated neurons (Zeng and Tietz, 1997). Chloride-loading was demonstrated to reverse the use-dependent shift in E_{Cl⁻} due to prolonged GABA activation (Ling and Bernardo, 1995). QX-314 (2 mM), an intracellular Na⁺ channel blocker, was also included to block the spontaneous firing of CA1 pyramidal neurons (Lupica, 1995; Zeng and Tietz, 1997).

s/mIPSC recordings. CA1 pyramidal cells, patched using 'blind' techniques, were voltage-clamped in continuous mode (cSEVC) using an Axoclamp 2A amplifier (Axon Instruments Inc., Foster City, CA). The current output was low-pass filtered at 10 KHz and amplified 100X. The amplified DC current was offset and further amplified 100X (FL4, 4 pole Bessel Filter, Dagan Corp., Minneapolis, MN). The signal was monitored continuously on-line using PClamp 6.0 Software interfaced

with a Digidata 1200 A/D converter (Axon Instruments Inc.) and stored on VCR tape with a VR100 Digital Recorder (Instrutech Corp., Mineola, NY) for off-line analysis. If series resistance varied by $> 80\%$, the recording was abandoned. In most cells, the amplitude of s/mIPSCs was constant for > 2 hours. To ensure that the relatively smaller events in FZP-treated neurons were reliably detected and to avoid voltage-clamp errors, sIPSCs and mIPSCs were recorded in each cell at three different holding potentials ($V_h = -50, -70, \text{ and } -90$ mV). At these negative membrane potentials, inward s/mIPSCs were detected in the presence of the glutamate antagonists APV ($50 \mu\text{M}$) and DNQX ($10 \mu\text{M}$). sIPSCs were recorded in one group of control ($n = 9$) and FZP-treated ($n = 10$) neurons. In another group of cells, mIPSCs were recorded in the presence of $1 \mu\text{M}$ TTX, after a 5-minute stable sIPSC recording was obtained.

s/mIPSCs analysis. For signal detection, the data on VCR tape was played back, amplified 10 X and low-pass filtered at 10 kHz. Off-line analysis was performed on an IBM compatible computer using Strathclyde CDR and SCAN software (J. Dempster, University of Strathclyde, Glasgow, Scotland). Non-stationary fluctuation analysis was carried out using NSAN software (Y. De Koninck, McGill University, Montreal, Canada). Spontaneous and miniature synaptic currents were analyzed from 2-minute segments of data acquired from each neuron under each recording condition. Detection threshold for individual sIPSC and mIPSC events was set just above the maximum recording system background noise. Data from individual neurons was omitted if the background noise exceeded 3 pA. Events with a duration shorter than 3 ms were also excluded (Lupica, 1995). For statistical comparisons of s/mIPSC amplitude and frequency, relative cumulative frequency distribution for the population of event amplitudes and inter-event intervals was compared between experimental and control groups using the Kolmogorov-Smirnov (K-S) test ($P \leq 0.01$) (Lupica, 1995; Otis and Mody, 1992). Curve fitting to estimate mIPSC decay kinetics was using a single exponential function [$y(t) = a * \exp(-t/\tau)$] or a bi-exponential function [$y(t) = a_1 * \exp(-t/\tau_1) + a_2 * \exp(-t/\tau_2)$] (J. Dempster, University of Strathclyde, Glasgow, Scotland). Non-stationary fluctuation analysis was carried out on mIPSCs as described by De Koninck and Mody (1992). Unitary current (i) and channel number (N) were estimated from the variance analysis using the equation $\sigma^2 = \bar{I}_M - I_M^2/N$ where i = unitary current; I_M = mean current and N = channel number. Unitary conductance (γ) was derived from the unitary current estimate.

Zolpidem effects on mIPSCs. Since $\alpha 1$ mRNA (Huang et al., 1994; Tietz et al., 1994) and protein (Chen et al., 1996) expression were selectively reduced in the CA1 region following 1 week FZP treatment, the ability of

the $\alpha 1$ -selective imidazopyridine, zolpidem (30 nM – $100 \mu\text{M}$), to enhance CA1 pyramidal cell mIPSCs was compared in control and FZP-treated cells. After 3 minutes baseline mIPSC activity was obtained zolpidem was added to the perfusate in increasing concentrations (4 – 10 concentrations/cell) for 8 minutes each. The final 3-minute segment of data under each concentration was used for off-line analysis of mIPSCs amplitude and decay kinetics and for non-stationary fluctuation analysis. The degree of zolpidem potentiation at each concentration was expressed as a fraction of the control response.

Evoked IPSCs. In other groups of rats sacrificed 2 days after FZP treatment was stopped, synaptic conductance was estimated from the current-voltage response to maximal stimulation of GABAergic interneurons. Voltage-clamp recordings (-70 to $+70$ mV) were made with micropipettes (6 – $10 \text{ M}\Omega$) filled with the same internal solution as described above. IPSCs were evoked, monosynaptically, in the presence $50 \mu\text{M}$ APV and $10 \mu\text{M}$ DNQX, with 0.1 ms constant-current pulses from a Master-8 stimulator (A.M.P.I., Jerusalem, Israel) coupled to an Iso-Flex constant current stimulus isolation unit (A.M.P.I.). Current was delivered through a concentric (75 mm O.D.), bipolar tungsten stimulating electrode placed at the str. oriens/str. pyramidale (SO/SP) border ≥ 0.5 from recording electrode. The mean synaptic conductance (γ), derived from the slope of the current-voltage relationship in each cell, was compared between FZP-treated and control groups by Student's t -test.

Intracellular recordings

GABA_B autoreceptor function. GABA_B autoreceptor function was measured by the degree of paired-pulse depression of CA1 pyramidal cell responses in slices from rats sacrificed 2 days after ending FZP treatment. Since postsynaptic GABA_A receptor function was shown to be profoundly impaired in FZP-treated neurons, GABA_B-mediated IPSPs, rather than GABA_A-mediated IPSPs, were used to evaluate paired-pulse depression (c.f. Davies et al. 1990; Mott and Lewis, 1994). Though the concentration-response of the selective GABA_B receptor agonist, baclofen, to inhibit CA1 population spikes was unchanged in FZP-treated slices (Xie and Tietz, 1991), a reduction in the amplitude and duration of the GABA_B receptor-mediated slow IPSP amplitude and duration was also detected (Zeng et al., 1995; Zeng and Tietz, 1997). Thus, to determine whether the postsynaptic GABA_B response was altered by FZP-treatment, the effect of the GABA_B receptor agonist, baclofen, to hyperpolarize CA1 neurons (Beck et al., 1995) was first evaluated between groups.

Baclofen-induced hyperpolarization. Intracellular recordings were made with filamented glass micropipettes (1.2 mm O.D. , 60 – $90 \text{ M}\Omega$, Sutter Instruments, San Rafael, CA) filled with 3 M potassium acetate. At

minimum 2 minute baseline ($V_H = -65$ mV; Axoclamp 2A, Axon Instruments, Foster City, CA) was recorded in the presence of 1 μ M TTX prior to baclofen (100 nM to 100 μ M) superfusion. Membrane potential was allowed to return to baseline during drug wash-out, prior to incrementing each baclofen concentration. Only one cell per slice was used. Concentration-response curves were constructed for each cell from the peak amplitude of the membrane hyperpolarization at each baclofen concentration and fit to a sigmoid curve using a four parameter logistic function (GraphPad, PRISM Software, San Diego, CA). The log EC_{50} s and the maximal responses for individual cells were compared by Student's *t*-test.

Paired-pulse depression of GABA_B-mediated IPSPs.

Monosynaptic IPSPs were evoked in CA1 neurons using the same electrode placement and stimulus parameters as described above. EPSPs were blocked with 50 μ M APV and 10 μ M DNQX. The GABA_A receptor antagonist, picrotoxin (50 μ M) was used to isolate the GABA_B receptor-mediated slow IPSP. Membrane potential was set to -60 mV. To activate the GABA_B autoreceptor, the amplitude of conditioning IPSPs was adjusted to 4.0–4.5 mV across control and FZP-treated neurons. Paired-pulse depression was induced by stimulating interneurons, twice with stimuli of equivalent intensity, at intervals from 250 ms to 1,250 ms and was expressed as the ratio of the peak amplitudes of conditioning and test responses. Paired-pulse depression curves at each concentration between groups was analyzed by ANOVA. Post-hoc analyses of individual data points were made using orthogonal contrasts ($P \leq 0.05$).

Biochemical studies

GABA release. To provide an additional measure of action-potential independent GABA release, the fraction of [³H]GABA released from pre-loaded hippocampal slices was evaluated following K⁺ depolarization. Four 200 μ m dorsal hippocampal slices, cut on a tissue chopper (Stoelting), were placed on a stainless steel grid in a wire mesh basket and were pre-incubated 10 minutes in 1.5 ml of pre-warmed (37° C), buffer under continuous oxygenation (95%O₂/5%CO₂). Slices were then incubated in 1.5 ml .23 μ M [³H]GABA (Amersham, Arlington Heights, IL, 59 Ci/mmol) plus 50 μ M aminooxyacetic acid for 30 minutes at 37°C. EDTA (30 μ M) was added in a few experiments to block Ca²⁺-mediated terminal release. Slices were washed 30 seconds in 1.5 ml buffer to remove excess [³H]GABA and transferred to a 1 ml filtration chamber (Millipore,). To prevent continued uptake of [³H]GABA during spontaneous and KCl-evoked release, buffer containing 200 μ M nipecotic acid was superfused at a constant rate of 1 ml/minute. Fractions of the perfusate were collected at 30-second intervals over 25 minutes. When the rate of release had reached steady-state (15 minutes), 1M KCl was injected

for 2 minutes via a septum (20 ml/minutes) with a calibrated syringe pump (Razel World Precision Instr. Inc., Sarasota, FL) (final concentration 25 mM). Fractions were counted 5 minutes in 5 ml CytoScint (ICN Biochemicals, Costa Mesa, CA). Slices were solubilized with 0.5 ml 0.5 N NaOH, sonicated, and the total [³H]GABA remaining was counted. Release per minute was expressed as a fraction of the total counts (dpm) available for release. Total [³H]GABA uptake (nmol/mg protein) was calculated from the total available for release as a fraction of total [³H]GABA in the incubation mixture. Protein estimates per slice were determined by the method of Lowry et al. (1951). The mean area under the peak was compared between groups by Students' *t*-test ($P \leq .05$).

GABA uptake into hippocampal synaptosomes. Methods for [³H]GABA uptake assays were modified from Abita et al. (1977). The hippocampus was isolated from FZP-treated rats sacrificed 2 days after ending treatment (n = 6) and matched control rats (n = 5). Each hippocampus was suspended by homogenization (10 strokes at 700 rpm) in 10 volumes of .32 M sucrose in 5 mM Tris HCl Buffer (pH 7.4, 0°C) and centrifuged at 1,200g for 5 minutes at 4°C (Beckman J21, Beckman, Palo Alto, CA). The supernatant was centrifuged at 23,000g at 20 minutes at 4°C. The P₂ pellet was resuspended in 1 ml ice-cold 0.32 M Sucrose in buffer and layered on a discontinuous sucrose gradient (0.8 M, 1.0 M, 1.2 M; 83,000g for 60 minutes at 4°C, Beckman SW27). Synaptosomes were collected at the 1.0/1.2 M sucrose interface and stored at 4°C until used. Synaptosomes were resuspended in 1 ml incubation buffer (in mM: 140 NaCl, 5 KCl 2.8 CaCl₂, 1.3 MgSO₄, 20 mM Tris-Cl, pH 7.4) plus 50 ml 0.6 M sodium valproate. The reaction was initiated with addition of 10 ml of [³H]GABA + unlabeled GABA to a final concentration of 10 or 50 mM per ml of synaptosomes and proceeded for 15 minutes. The time-course and concentrations for maximal GABA uptake were determined in preliminary assays. Non-specific uptake was in the presence of 500 mM nipecotic acid. The incubation mixture was filtered over 0.45 mm Millipore filters, pre-soaked 2 hours in 1% BSA. Filters were washed 2X with buffer, air-dried, and counted 5 minutes in 5 ml CytoScint. Protein concentration was determined by the method of Lowry et al. (1951).

Drug application and drug solutions

All drug stock solutions were made at 100X the final concentration and added to the perfusate with a syringe pump (Razel, World Precision Instruments, Inc., Sarasota, FL) at a rate of 25–75 μ l/minute to achieve their final concentration. Drugs were dissolved in distilled water or as indicated. FZP (flurazepam dihydrochloride) (pH 6.4); APV (DL-2-amino-5 phosphonovaleric acid), DNQX (6,7-dinitroquinoxaline-2,3-dione) in DMSO (to a final concentration of $\leq .001\%$), TTX (tetrodo-




Fig. 1. Effects of chronic FZP treatment on sIPSC amplitude and frequency in CA1 neurons from rats sacrificed 2 days after treatment. **A:** sIPSCs recorded from a control (top) and a FZP-treated (bottom) CA1 pyramidal cell. Cells were recorded in the presence of 50 μ M APV and 10 μ M DNQX. FZP-treated neurons showed a decrease in sIPSC amplitude and frequency when compared to the control neurons. **B:** Representative average sIPSCs from a control (n = 191 events) and a FZP-treated neuron (n = 98 events). One week FZP-treatment resulted in a reduction in average sIPSC amplitude. **C,D:** Relative cumulative frequency distributions of sIPSCs (C) amplitudes and (D) inter-event interval (1/frequency) in control (n = 9) and FZP-treated (n = 10) CA1 neurons. C: The distribution of sIPSC amplitudes in FZP-treated neurons was shifted significantly to the left indicating a decrease in the proportion of higher amplitude events. The distribution of inter-event intervals was shifted significantly to the right, indicating an increased proportion of longer intervals between events, corresponding to a decrease in the frequency of sIPSCs in FZP-treated CA1 neurons (Kolmogorov-Smirnov test; $P < 0.001$).

toxin), (+)-bicuculline methiodide, and (\pm)baclofen were purchased from Research Biochemicals International (Natick, MA). Picrotoxin was from Sigma Chemical Co. (St. Louis, MO). QX-314 was from Alamone Labs (Jerusalem, Israel). Zolpidem was kindly provided by Synthelabo Recherche (Bagneux, France). Buffer chemicals were from Sigma or Fisher Scientific Co. (Pittsburgh, PA).

RESULTS

Characteristics of sIPSCs and mIPSCs

Whole-cell patch-clamp recordings were made from FZP-treated and control CA1 neurons in hippocampal slices from young adult rats (240–260 g). Spontaneous inward s/mIPSCs were observed in neurons voltage-clamped at negative membrane potentials (Figs. 1A and 2A). Since APV (50 μ M) and DNQX (10 μ M) were perfused throughout the entire recording period, any mixed s/mEPSCs were eliminated. When bicuculline methiodide (BMI, 5 μ M), a GABA_A receptor competitive antagonist, was superfused, sIPSCs were completely blocked. sIPSCs reappeared after BMI washout (n = 4, data not shown). After TTX (1 μ M) was introduced to the bath for 5 minutes, most events of larger amplitude disappeared (Fig. 2A), indicating that the occurrence of sIPSCs was dependent on the spontaneous firing of

interneurons. The remaining events were action potential-independent mIPSCs and had a lower amplitude, and a lower frequency of appearance as compared to sIPSCs. The averaged amplitude of sIPSCs after TTX perfusion (mIPSCs) was significantly ($P < 0.01$) smaller than before TTX perfusion (sIPSCs). The relative cumulative frequency distributions for event amplitudes were significantly ($P < 0.001$) shifted toward smaller amplitude events, indicating a decrease in event amplitude after TTX superfusion. With a symmetric Cl⁻ concentration inside and outside the neuronal membrane, mIPSCs reversed their polarity at about 0 mV, as predicted by the Nernst equation (Fig. 2B, n = 4). The voltage-dependency ($V_h = -90$ to $+90$ mV) of mIPSCs is also shown in the current-voltage (I-V) response of the same control cell in Figure 2B. Similar observations were found during sIPSC recordings (n = 3, data not shown).

Effects of chronic FZP treatment on CA1 pyramidal cells GABA_A receptor-mediated currents sIPSCs recorded 2 days after 1 week FZP treatment

One group of paired-handled FZP-treated and control rats, which were sacrificed 2 days after 1 week FZP treatment, were used for recording sIPSCs. Figure 1A




Fig. 2. Effects of chronic FZP treatment on mIPSC amplitude and frequency in CA1 neurons from rats sacrificed 2 days after treatment. **A:** Representative traces from a control (top) and a FZP-treated neuron (bottom). The data were recorded in the presence of 50 μ M APV, 10 μ M DNQX, and 1 μ M TTX. Note the decrease in mIPSC amplitude, without an effect on mIPSC frequency in the FZP-treated neuron. One-third of FZP-treated neurons recorded had no events. **B:** I-V curve (top) constructed from average mIPSCs in a control cell showing that mIPSC amplitude and polarity varied as a function of membrane holding potential (-90 mV to +90 mV). Averaged mIPSCs from a control ($n = 63$ events) and a FZP-treated neuron ($n = 109$ events) are also shown (bottom). **C,D:** Relative cumulative frequency distribution of mIPSC amplitudes (C) and inter-event intervals (D) in CA1 neurons from control ($n = 9$) and FZP-treated ($n = 9$) rats. The FZP-treated neurons showed a significant (Kolmogorov-Smirnov test; $P < 0.001$) leftward shift of the amplitude distribution (C), indicating a decrease in mIPSC amplitude after chronic benzodiazepine treatment. There was no shift in the inter-event interval distribution (D) (Kolmogorov-Smirnov test; $P > 0.01$).

shows representative sIPSCs traces recorded from a control and a FZP-treated neuron. Each neuron was sequentially voltage-clamped at $V_h = -90, -70,$ and -50 mV. At each membrane holding potential, averaged sIPSCs, recorded in neurons from rats 2 days after one week FZP treatment, were significantly reduced (58–64%) in amplitude [-50 mV: Control ($n = 11$), -43.1 ± 3.2 pA; FZP-Treated ($n = 8$), -17.7 ± 1.6 pA; -70 mV: Control, -58.7 ± 4.6 pA; FZP-Treated, -24.4 ± 4.4 pA; -90 mV: Control, -73.1 ± 7.3 pA; FZP-Treated, -30.0 ± 4.4 pA] and appeared less frequently when compared to those detected in control neurons. The frequency distribution of mean \pm S.E.M. sIPSCs amplitudes at $V_h = -70$ mV showed a loss of both small and large amplitude sIPSCs in FZP-treated neurons (data not shown). Relative cumulative frequency distributions of event amplitude (Fig. 1C) and inter-event interval (Fig. 1D) were constructed between control ($n = 9$) and FZP-treated ($n = 10$) neurons ($V_h = -70$ mV). Compared to control neurons, there was a significant shift in the sIPSC amplitude distribution toward smaller amplitude events at $V_h = -90$ mV ($P < 0.001$), -70 mV ($P < 0.001$), and -50 mV ($P < 0.001$) in FZP-treated neurons. Inter-event interval distributions of sIPSCs were significantly shifted towards longer intervals (decreased frequency) at $V_h = -90$ mV ($P < 0.001$), -70 mV ($P < 0.001$), and -50

mV ($P < 0.001$) in FZP-treated neurons as compared to control neurons.

mIPSCs recorded 2 days after 1 week FZP treatment. mIPSCs were recorded in another group of FZP-treated ($n = 9$) and control ($n = 9$) neurons (Fig. 2A). mIPSC event amplitudes in FZP-treated neurons were significantly smaller than control mIPSC event amplitudes indicated by the leftward shift of the relative cumulative frequency distribution of mIPSC amplitudes (Fig. 2C, $V_h = -70$ mV). Averaged mIPSC amplitude in control neurons ($n = 26$) ranged from -5.5 pA to -60.7 pA (Mean -25.7 ± 2.9 pA; Median -23.3 pA). In a large sample of FZP neurons recorded, 32% of cells (21/64) had no detectable mIPSC events, as reported by Poisbeau et al. (1997). In FZP-treated neurons in which events were detected, event amplitude ranged from -6.3 to -21.2 pA (Mean: -11.9 ± 0.7 pA; Median -11.1 pA). Analysis of the relative cumulative frequency distributions of event amplitudes recorded in hippocampal CA1 neurons after 1 week FZP administration indicated a significant decrease in event amplitudes at $V_h = -90$ mV ($P < 0.001$), -70 mV ($P < 0.001$), and -50 mV ($P < 0.001$). There were no significant differences between control and FZP-treated neuron mIPSC inter-event interval distributions (Fig. 2D, $V_h = -70$ mV) at any holding potential recorded [$V_h = -90$ mV ($P > 0.01$), -70

TABLE I. mIPSC kinetics and unitary conductance in CA1 pyramidal cells*

Monophasic Fit			Unitary Conductance/ Channel Number		
Group (# cells)	Amp. (pA)	τ (msec)	Group (# cells)	γ (pS)	N
Control (n = 9)	-25.6 ± 5.3	25.1 ± 1.7	Control (n = 12)	27.0 ± 4.8	45.6 ± 7.2
FZP-Treated (n = 13)	-10.4 ± 2.1	26.9 ± 4.3	FZP-Treated (n = 11)	5.0 ± 0.6	50.1 ± 4.0
p value	<0.01*	0.53	p value	<0.01*	0.60
Biphasic Fit					
Group (# cells)	A ₁ (pA)	τ_1 (msec)	A ₂ (pA)	τ_2 (msec)	
Control (n = 17)	-12.2 ± 2.4	10.2 ± 1.0	-14.4 ± 2.1	33.0 ± 2.0	
FZP-Treated (n = 20)	-5.0 ± 0.6	11.1 ± 1.1	-8.4 ± 0.9	34.1 ± 2.3	
p value	p < 0.02*	p = 0.64	p = 0.07	p = 0.65	

Mean (\pm S.E.M.); asterisks denote significant difference at $p \leq .05$.

mV ($P > 0.01$), and -50 mV ($P > 0.01$)]. The amplitude and decay kinetics of averaged mIPSCs was compared in 26 control and 34 FZP-treated cells. As with sIPSCs there was a significant, ~60% reduction in the averaged mIPSC amplitude in FZP-treated cells (Table I). The mIPSC decay constant (t) was in the range reported previously for dentate neuron mIPSCs recorded at room temperature (De Koninck and Mody, 1992; Otis and Mody, 1992). Based on a comparison of residual variances (R^2) among cells within groups, a bi-exponential decay function best fit mIPSC decay in similar fractions of control and FZP-treated neurons (control: 17/34 cells, 65%; FZP-treated: 21/34 cells, 62%). There were no significant differences in either the monophasic or the biphasic decay constants between the experimental groups of cells (Table I).

sIPSC and mIPSCs recorded 7 days after 1 week FZP treatment. sIPSCs (Fig. 3A and B) and mIPSCs (Fig. 3C and D) were recorded at $V_h = -90$ mV, -70 mV, and -50 mV in FZP-treated neurons from a separate group of rats sacrificed 7 days after the end of one week FZP-treatment and compared to responses from pair-handled control rats. At each membrane holding potential, there were no significant differences ($P > 0.01$) between the control (n = 7) and FZP-treated (n = 8) IPSC amplitude or inter-event interval relative cumulative frequency distributions. Similarly, there were no significant differences ($P > 0.01$) in mIPSC (control, n = 6; FZP-treated, n = 6) amplitude or inter-event interval distributions.

Studies related to presynaptic regulation of GABA release

[³H]GABA uptake and release. There were no significant differences in the rate of spontaneous release or the fraction of [³H]GABA released by KCl depolarization of hippocampal slices from FZP-treated vs. control rats (Fig. 4). There was also no difference in the amount of [³H]GABA taken up into hippocampal slices subjected to KCl depolarization. Subsequent GABA uptake assays revealed no significant difference in the amount of [³H]GABA taken up into hippocampal synaptosomes

from FZP-treated or control rats (Fig. 4 inset, $P > .05$ Student's *t*-test).

Baclofen-induced hyperpolarization. Superfusion of baclofen induced membrane hyperpolarization in CA1 neurons accompanied by a small decrease in membrane resistance (Fig. 5A and B). The amplitude of the baclofen-induced hyperpolarization increased in a dose-dependent manner. There were no significant differences between the log EC₅₀s (Control, -5.5 ± 1.0 μ M; FZP-treated, -5.8 ± 1.0 μ M, $P = 0.7$) or maximal responses (Control, 10.1 ± 1.7 mV; FZP-treated, 10.2 ± 1.0 mV, $P = 0.9$) derived from individual control and FZP-treated neuron responses to baclofen fitted to a sigmoidal curve (Fig. 5C). The EC₅₀s and maximal responses estimated from the averaged concentration-response curves were 1.1 mM (95% C.I. = 0.5–2.5 μ M) and 9.4 ± 0.7 mV in control cells and 1.4 mM (95% C.I. = 0.3–7.0 μ M) and 10.1 ± 1.7 mV in FZP-treated cells (Fig. 5A).

Paired-pulse depression of GABA_B-mediated IPSPs. In the presence of 50 μ M APV and 10 μ M DNQX, addition of 50 μ M picrotoxin to the ACSF blocked the fast IPSP, leaving the slow GABA_B-mediated IPSP. The amplitude of conditioning IPSPs was not significantly different between groups (Control: 4.7 ± 0.05 mV; FZP-treated: 4.5 ± 0.03 mV, $P = 0.18$). In all cells, application of paired-pulse stimuli suppressed the amplitude of the second, slow IPSP relative to the first, indicating activation of presynaptic GABA_B autoreceptors (Fig. 5D and E). The degree of paired-pulse depression across cells from both groups decreased significantly as interpulse interval increased ($P < 0.001$). The degree of paired-pulse depression of slow IPSPs was not significantly different between FZP-treated and control cells across all interstimulus intervals (Fig. 5F, $P = 0.85$).

Studies related to postsynaptic effects of GABA-mediated conductance

Evoked IPSCs. Maximal activation of GABAergic interneurons in the presence of excitatory amino acid antagonists resulted in GABA_A receptor-mediated IP-




Fig. 3. Effects of chronic FZP treatment on sIPSC and mIPSC amplitude and frequency in CA1 neurons from rats sacrificed 7 days after treatment. **A,B:** Relative cumulative frequency distribution of sIPSC (A) amplitudes and (B) inter-event intervals in CA1 neurons from control and FZP-treated rats. sIPSCs recorded in control ($n = 7$) and FZP-treated neurons ($n = 8$) showed no significant difference between their amplitude or inter-event interval distributions. **C,D:** Relative cumulative frequency distribution of mIPSC amplitudes (C) and inter-event intervals (D) in CA1 neurons from control and FZP-treated rats. mIPSCs recorded in control ($n = 6$) and FZP-treated neurons ($n = 6$) also showed no significant difference between their amplitude or inter-event interval distributions (Kolmogorov-Smirnov test; $P > 0.01$).




Fig. 4. KCl-evoked $[^3\text{H}]\text{GABA}$ release from hippocampal slices. Slices were incubated for 30 minutes at 37°C with $0.23\text{ mM } [^3\text{H}]\text{GABA}$. When $[^3\text{H}]\text{GABA}$ release reached steady-state (15 minutes), neurons were depolarized for 2 minutes with 25 mM KCl . There was no difference in the fraction of $[^3\text{H}]\text{GABA}$ released from control slices (filled circles) vs. slices from FZP-treated rats (open circles) ($P < .05$). Inset: $[^3\text{H}]\text{GABA}$ uptake into hippocampal synaptosomes from control (filled bars) and 1 week FZP-treated rats (open bars) sacrificed 2 days after treatment. There were no significant differences in $[^3\text{H}]\text{GABA}$ (10 or $50\text{ }\mu\text{M}$) uptake into synaptomes between experimental groups ($P < .05$).

SCs in voltage-clamped ($V_h = -70$ to $+70\text{ mV}$) CA1 pyramidal cells. The IPSCs evoked in cells from rats killed 2 days after ending oral FZP administration were compared to those in cells from matched control rats (Fig. 6A). The reversal potential for the E_{IPSC} was 0 mV in both groups. Outward currents recorded at positive holding potentials were greater in magnitude than at comparable negative potentials indicating outward rectification (Fig. 6B). The slope of the I-V relationship was

used as an estimate of synaptic conductance and was significantly lower in FZP-treated vs. control cells [2.9 ± 1.0 ($n = 6$) vs. 10.8 ± 2.2 ($n = 6$); $P = .008$].

Unitary conductance and channel number were estimated in control ($n = 12$) and FZP-treated ($n = 11$) CA1 neurons 2 days after the end of 1 week FZP treatment by the variance analysis of mIPSC decay (Table I). Unitary conductance (γ) was derived from the unitary current estimate. In control cells the conductance esti-




Fig. 5. Evaluation of pre- and postsynaptic GABA_B receptor function. **A–C:** Intracellular recordings were made in FZP-treated and control CA1 pyramidal neurons to evaluate the concentration-dependent effects of baclofen. Representative traces of baclofen's (3, 10, 30, and 100 μ M) effect on A (control) and B (FZP-treated CA1 neurons) (membranes potential, -65 mV). Superfusion of baclofen resulted in membrane hyperpolarization accompanied by a small decrease in membrane resistance as negative current pulses (4 nA) were passed through the recording electrode. **C:** Baclofen concentration-response relationship. Baclofen (10 nM– 100 μ M) was added to the superfusate in increasing concentrations, in the presence of 1 μ M TTX. The averaged (\pm S.E.M.) data were fit to a sigmoidal curve (control: filled circles, $EC_{50} = 1.1$ μ M; FZP-treated, open circles, $EC_{50} = 1.4$ μ M). Mean log EC_{50} s derived from individual cell's concentration-

responses indicated no significant differences between groups ($P = 0.70$). **D–F:** Paired-pulse depression of GABA_B-mediated IPSCs. Representative traces of the response of D (control) and E (FZP-treated neurons) to paired stimulation (250–1,250 ms interpulse interval) of GABAergic terminals at the str. radiatum/str. lacunosum moleculare border. Responses were elicited in the presence of 50 μ M APV, 10 μ M DNQX, and 50 μ M picrotoxin. Following paired-pulse stimulation the amplitude of the second response was suppressed. **F:** Relationship between paired-pulse depression and inter-event interval in control ($n = 6$) and FZP-treated ($n = 6$) neurons. The percent inhibition of the late IPSP varied inversely as a function of interstimulus interval and was not significantly different between control (filled circles) and FZP-treated (open circles) CA1 neurons groups ($P > .05$).

mates ranged from 7 pS to 54 pS whereas in FZP-treated cells conductance estimates ranged from 2 to 9 pS. There was no significant difference in the mean channel number (N) (Table I) between control and FZP-treated cells.

Zolpidem potentiation of GABA-mediated currents.

Zolpidem (30 nM–100 μ M) concentration-dependently prolonged the decay of mIPSCs in CA1 pyramidal cells (Fig. 7A and C). In control neurons ($n = 7$) the concentration-effect of zolpidem to prolong mIPSC decay showed two plateaus. However, the data could not be fit using a two-site equation. The effect of zolpidem to enhance mIPSC decay was significantly reduced in FZP-treated neurons ($n = 7$) (Fig. 7C). Zolpidem (100 μ M) enhance-

ment of mIPSC amplitude in control cells indicated an average maximal potentiation of $156.7 \pm 14.7\%$ (Fig. 7C). In one control cell, with a low estimated unitary conductance ($\gamma = 7$) the maximal zolpidem (10 μ M) potentiation was 212%. Since the baseline mIPSC amplitude in CA1 pyramidal cells from FZP-treated rats was $\sim 40\%$ of that recorded in control cells, the FZP-treated response was normalized to the control response for comparison (Fig. 7D).

DISCUSSION

These *in vitro* studies in hippocampal CA1 pyramidal cells suggested that both GABAergic pre- and postsyn-




Fig. 6. Maximal IPSCs were evoked in CA1 pyramidal cells by monosynaptic stimulation of GABAergic terminals at the str. oriens/str. pyramidale border in the presence of excitatory amino acid antagonists. Neurons were recorded with 130 mM CsCl in the whole cell pipette. During stimulation V_h was varied from -70 to +70 mV. **A:** Representative traces of IPSCs evoked in a control (dashed line) or a FZP-treated (solid line) cell at $V_h = -70$ and +70 mV. Note the outward

rectification of the GABA_A receptor-mediated current, most evident in the control traces. **B:** With symmetrical [Cl⁻], the reversal potential of the E_{IPSC} was 0 mV in both groups. There was a significant decrease in the slope of the I-V relationship in CA1 pyramidal cells derived from rats killed 2 days after oral FZP treatment was withdrawn ($n = 10$), relative to cells from pair-handled control rats ($n = 9$) indicating a decrease in synaptic conductance (γ).

aptic mechanisms may contribute to benzodiazepine anticonvulsant tolerance in vivo. Taken together, the results of whole-cell, intracellular, and biochemical studies suggested that reduced presynaptic GABAergic function in the hippocampus was related to decreased interneuron activity. Confirming our preliminary studies of m/sIPSCs in this model (Zeng et al., 1995), profound changes in the function of the postsynaptic GABA_A receptor were indicated by the 60% reduction in s/mIPSC amplitude and the absence of mIPSCs in one-third of cells recorded from FZP-treated rats. A reduction in postsynaptic GABA_A receptor function was further supported by the decreased synaptic and unitary conductance measured in CA1 neurons. Moreover, tolerance was demonstrated in CA1 pyramidal cells in vitro by the reduced capacity of the GABA_A receptor $\alpha 1$ subtype-selective ligand, zolpidem, to prolong mIPSC decay, paralleling the discretely localized reductions in CA1 pyramidal cell $\alpha 1$ subtype mRNA and protein expression in this animal model (Chen et al., 1996; Huang et al., 1994; Tietz et al., 1994).

Accumulating evidence suggests that GABA released from a diverse array of GABAergic interneurons (c.f., Freund and Buszák, 1996) interacts with heterogeneous populations of GABA_A receptors (Fritschy and Möhler, 1995; Sperk et al., 1997; Wisden et al., 1992) located on multiple, subcellular compartments of hippocampal pyramidal cells (Freund and Buszák, 1996; Freund and Gulyás, 1997; Miles et al., 1996; Nusser et al., 1996), resulting in functionally heterogeneous GABA

responses in the hippocampus (Alger and Nicoll, 1982; Kapur and Macdonald, 1996; Miles et al., 1996; Pearce et al., 1995; Schönrock and Borman, 1993). The amount of GABA released is related to the level of presynaptic GABAergic interneuron network activity (Edwards and Sakmann, 1990; Hájos and Mody, 1997; Otis and Mody, 1992; Ropert et al., 1990) as well as random, i.e., tonic GABA release. Whereas the frequency of sIPSCs is a sum of the interneuron network activity, the latter process is reflected in the mIPSP frequency and was not altered in FZP-treated CA1 neurons (Fig. 2). KCl-evoked release was a sensitive measure of increased GABA release from hippocampal slices following chronic diazepam treatment (Hitchcott et al., 1990). However, neither KCl-evoked release, due to direct terminal depolarization, nor [³H]GABA uptake, were altered by FZP-treatment (Fig. 4). Presynaptic GABA_B autoreceptor function, which plays a role in feedback regulation of GABA release, and can be reflected in the degree of paired-pulse depression (Isaacson et al., 1993; Mott and Lewis, 1994; Pearce et al., 1995), was also unchanged by chronic FZP treatment (Fig. 5). Taken together, these negative findings suggested that an alteration in GABAergic terminal release processes may not be central to benzodiazepine tolerance.

The change in sIPSC frequency in FZP-treated cells may relate to a regulation of interneuron network activity in the hippocampus, i.e., the change in excitability in those interneurons targeting CA1 pyramidal cells. The excitability of these interneurons may be




Fig. 7. Effect of 1 week FZP administration on zolpidem potentiation of mIPSC decay and amplitude. **A:** Representative traces of the decay phase of averaged mIPSCs recorded from a control (bottom traces) and a FZP-treated (top traces) neuron during superfusion of increasing concentrations of zolpidem (300 nM–10 μM). At each zolpidem concentration, the average mIPSC was normalized to the average mIPSC amplitude of the control neuron. The best fit line to the decay, derived from the double exponential equation: $y(t) = a_1 \cdot \exp(-t/t_1) + a_2 \cdot \exp(-t/t_2)$, is superimposed over each trace. **B:** Representative averaged mIPSCs in a control (top traces) and FZP-treated (bottom traces) cell during zolpidem superfusion (30 nM–100 μM). **C:** Concentration-response curve of the effect of zolpidem to

prolong mIPSC decay. Data are expressed as a percent of the baseline average mIPSC decay recorded in the absence of zolpidem. Two plateaus were evident in the zolpidem concentration-response curve constructed from control cells ($n = 7$). There was a significant reduction in the ability of zolpidem to enhance mIPSC decay in FZP-treated cells ($n = 7$). **D:** The concentration-response curve of the effect of zolpidem to potentiate average mIPSC amplitude in the same control and FZP-treated CA1 pyramidal cells. Since mIPSC amplitude was significantly reduced in FZP-treated cells, the response in FZP-treated cells was normalized to the mean average mIPSC amplitude in the 7 control cells in the absence of zolpidem. The non-normalized response in FZP-treated cells is also shown (dashed line).

regulated by a change in their membrane properties or by ionotropic and metabotropic receptor-mediated, excitatory inputs, and GABA_A receptor-mediated inhibitory inputs (Freund and Gulyás, 1997; Lacaille et al., 1989; Sah et al., 1990; Samulack et al., 1993; Whittington et al., 1995). Since sIPSC frequency was not altered in the presence of ionotropic glutamate antagonists (Otis and Mody, 1992) and was superfused in the present experi-

ments, these receptors were not candidates for regulation of sIPSC frequency in FZP-treated rats. Recent electrophysiological, morphological, and immunohistochemical studies have established GABA_A receptor-mediated inhibitory connections among hippocampal interneurons. For example, sIPSCs can be recorded in interneurons (Hájos and Mody, 1997). The positive $\alpha 1$, $\beta 2$, and $\gamma 2$ GABA_A receptor subtype immunoreactivity

of subclasses of hippocampal interneurons (Gao and Fritschy, 1994; Moreno et al., 1992; Sperk et al., 1997) provides a possible molecular substrate for the regulation of interneuron excitability by chronic benzodiazepine administration, i.e., an increase in GABAergic inhibitory input to specific interneuron classes may result in a depression of their activity. In fact, $\alpha 1$ mRNA expression was downregulated on one subclass of interneurons at the str. pyramidale/str. oriens border after FZP-treatment (Tietz et al., in press). The importance of this subclass to CA1 pyramidal cell inhibition is not yet known. Calretin (CR)-positive interneuron-selective (IS) GABAergic interneurons, immunoreactive for the $\alpha 1$ -subtype antibody, which may mediate gamma (~ 40 Hz) rhythms in the hippocampus (compare Freund and Buszák, 1997; Jeffreys et al., 1996) are possible candidates. Other classes of interneurons receive GABAergic inputs from afferent pathways extrinsic to the hippocampus (Freund and Buszák, 1996; Lacaille et al., 1989;) and may mediate theta rhythms in CA1 neurons (Soltész and Deschénes, 1993). Interestingly, FZP-treatment was shown to modulate power spectra in the theta frequency in vivo (Poisbeau et al., 1997). Additionally, GABA-mediated depolarizing responses were recorded in $\alpha 1\beta 2\gamma 2$ -immunopositive interneurons (Gao and Fritschy, 1994; Moreno et al., 1994; Guitiérrez et al., 1994; Sperk et al., 1997) in the hilus, which synchronized GABAergic responses recorded in dentate granule cells. Similar interneuron subclasses may exist in the CA1 region (Michelson and Wong, 1991). Thus, both electrophysiological and immunocytochemical evidence supports the possibility that altered sIPSC frequency in FZP-treated CA1 neurons may be related to a change in interneuron activity due to regulation of inhibitory inputs onto interneurons, resulting in a decrease in tonic GABAergic function.

Studies of maximally-evoked IPSCs (Fig. 6) indicated a reduction in synaptic conductance in FZP-treated rats. A change in synaptic conductance could reflect a decreased GABA concentration at the synaptic cleft or a decreased Cl^- channel conductance. The lack of change in mIPSC frequency and the lack of modulation of GABA release or uptake made the first possibility unlikely. The mean unitary conductance estimated in control CA1 pyramidal cells (27 pS) was similar to that reported in single-channel studies in hippocampal culture (8 to 54 pS, Eghbali et al., 1997) and to that found under similar conditions in dentate granule cells (20 pS, De Koninck and Mody, 1992) and CA3 pyramidal cells (31 pS, Poncer et al., 1996). Unitary conductance was significantly greater in control CA1 cells in comparison to FZP-treated cells (6 pS). The $\sim 75\%$ reduction in the unitary conductance estimate (Table I) strongly suggested that GABA_A receptor channel conductance was reduced following FZP treatment. Since conductance levels may reflect variations in GABA_A receptors subunit composition (Sigel et al., 1990; Verdoorn et al.,

1990), in particular among hippocampal principle cell types (Fritschy and Mähler, 1995; Sperk et al., 1997; Wisden et al., 1992), the large reduction in unitary conductance in FZP-treated CA1 pyramidal cells could be explained by a switch in GABA_A receptor subunit composition. Nonetheless, a test of this hypothesis will require more direct measures of native GABA_A receptor subunit composition in individual pyramidal neurons in relation to changes in single channel conductance.

Zolpidem had the predicted effect to prolong mIPSC decay in CA1 pyramidal cells (De Koninck and Mody, 1992; Otis and Mody, 1992; Poisbeau et al., 1997; Poncer et al., 1996). Concentration-response studies also revealed a multiphasic effect of zolpidem on mIPSC decay, which may relate its differential affinity for GABA_A receptor subunit variants ($\alpha 1 \gg \alpha 2, \alpha 3 \gg \alpha 5$; compare Sieghart, 1995) and the detection of multiple [³H]zolpidem binding sites in the hippocampus (Ruano et al., 1992). The decreased potency of zolpidem to potentiate GABA-induced currents in acutely dissociated CA1 pyramidal cells of chronic diazepam-treated rats (Itier et al., 1996) and the decreased ability of zolpidem to prolong mIPSC decay (Fig. 7C) may be explained by the localized decrease in $\alpha 1$ mRNA and protein expression in this model. The smaller degree of potentiation at lower concentrations may reflect zolpidem's decreased relative potency at an altered $\alpha 1$ subunit. Zolpidem's capacity to increase mIPSC amplitude is controversial (Fig. 7D). Benzodiazepines were shown to have no effect on mIPSC amplitude (De Koninck and Mody, 1992; Mellor and Randall, 1997; Otis and Mody, 1992; Poncer et al., 1996), suggesting that GABA saturates the synaptic cleft (Maconochie et al., 1994). Conversely, Perrais and Ropert (1997) reported that zolpidem (100 nM–100 μM) potentiated mIPSC amplitude ($\sim 140\%$ of control) in cortical pyramidal cells, cerebellar Purkinje cells, and dentate granule cells recorded at 22°C, consistent with the idea that intrinsic variation in transmitter concentration and variance in stochastic channel properties can contribute to the variance in mIPSC amplitude (Bekkers et al., 1990; Frerking et al., 1995). In control CA1 pyramidal cells, zolpidem enhanced mIPSC amplitude to a maximum of 156% (Fig. 7D), suggesting that GABA concentration may not be saturating at CA1 pyramidal cells synapses in the present study or that, similar to diazepam's effect on GABA-gated currents in hippocampal culture, zolpidem might increase Cl^- channel conductance (Eghbali et al., 1997). For example, one cell in which conductance was initially low (8 pS) was potentiated to 212% of control by 10 μM zolpidem. The ability of zolpidem to enhance IPSCs suppressed by chronic FZP treatment suggested that either GABA_A receptor functionality could be partially restored or that another GABA_A receptor isoform, presumably $\alpha 2$ -containing, was preferentially activated.

A reduction in s/mIPSCs amplitude could reflect a change in GABA_A receptor number or in channel conductance (DeKoninck and Mody, 1992; Nusser et al., 1997). However, estimates of GABA_A receptor channel number (N) derived from non-stationary fluctuation analysis (Table I) indicated no decrease in GABA_A receptor number following chronic benzodiazepine treatment. This finding was consistent with the absence of a change in [³H]GABA binding in the CA1 region of the hippocampus following the same FZP-treatment (Chen et al., 1995). Alternatively, the functional changes detected in FZP-treated CA1 pyramidal cells may have their basis in a change in postsynaptic GABA_A receptor subunit composition. Investigations aimed at establishing whether such a switch occurs have demonstrated a variety of changes in subtype mRNA expression following different chronic benzodiazepine treatments, primarily in cerebral cortex (Heninger et al., 1990; Holt et al., 1996; Impagnatiello et al., 1996; Kang and Miller, 1991; O'Donovan et al., 1992; Zhao et al., 1994). A localized decrease in $\alpha 1$ and $\beta 3$ subtype mRNA and protein expression was first detected in the CA1 pyramidal region after 1 week FZP treatment (Chen et al., 1996; Tietz et al., 1994, in press). The decreased $\alpha 1$ subunit mRNA content was replicated by RT-PCR analysis of the hippocampus from diazepam-treated rats (Impagnatiello et al., 1996). The functional consequences of such a switch in subunit composition have been investigated in heterologous expression systems. Kinetic analyses of GABA-gated currents in recombinant receptors have suggested that the structural determinants for the molecular transitions associated with ligand binding, resulting in channel activation and gating, may be localized to the α subunit (Gingrich et al., 1995). The β subunit, in addition to its role as a target for GABA binding (compare Smith and Olsen, 1995), plays a critical role in subcellular targeting of assembled receptors to regulate receptor localization or clustering (Connolly et al., 1996; Perez-Velazquez and Angelides 1993) and may also modulate GABA/benzodiazepine pharmacology (Ducic et al., 1995; Sieghart, 1995; Sigel et al., 1990). Chronic benzodiazepine treatment may remodel the GABA_A receptor by altering subunit composition from one with a higher affinity for GABA and benzodiazepines to one with a lower affinity and could account for the decreased GABA_A agonist and benzodiazepine potency in the CA1 region of the hippocampus of FZP-tolerant rats (Fig. 7C; Xie and Tietz, 1992). Such a switch could also account for the allosteric uncoupling of GABA/benzodiazepine binding sites associated with chronic benzodiazepine treatment (c.f., Barnes, 1996) but does not preclude the possibility that altered post-translational processes, e.g., protein phosphorylation (Brown and Bristow, 1996; Klein et al., 1994; Primus et al., 1996; Tietz et al., in press), may contribute to the molecular transitions at the GABA_A receptor associated with decreased GABAergic function.

Tolerance to the action of benzodiazepines to inhibit pentylentetrazol-induced seizures in vivo was measured up to 4 days after 1 week FZP treatment and had disappeared when measured at 7 days (Rosenberg, 1995; Rosenberg et al., 1985;) when functional changes in CA1 neurons were reversed (Fig. 3). Poisbeau et al. (1997), using a slight modification of this FZP treatment regimen, evaluated changes in unitary current in CA1 neurons and dentate granule cells at several time-points after benzodiazepine administration was stopped. Reductions in unitary current in CA1 pyramidal cells were augmented on days 3–5 after the drug was removed and returned to control values by the 6th day. Since spontaneous or precipitated abstinence signs were not evident following FZP withdrawal (Tietz and Rosenberg, 1988), changes in conductance may not be related to benzodiazepine dependence. There was no change in unitary current in dentate granule cells exposed to FZP in vivo (Poisbeau et al., 1997). Moreover, exposure of hippocampal slice cultures to midazolam had no effect on CA3 pyramidal cell unitary conductance or on the ability of midazolam to prolong mIPSC decay. However, the inability to demonstrate midazolam tolerance in vitro may account for the unchanged unitary conductance and may not be surprising since midazolam tolerance is difficult to induce in vivo (Ramsey-Williams et al., 1994). Nonetheless, $\alpha 1$ mRNA expression was reduced in all three principle cell groups while rats were still consuming FZP, yet the reduction in mRNA expression persisted only in CA1 pyramidal cells, the sole hippocampal cell group in which a change in function due to chronic benzodiazepine exposure has been detected.

ACKNOWLEDGMENTS

Portions of this work have appeared in abstract form: *Soc. Neurosci. Abstr.* 17:264, 1991; *Soc. Neurosci. Abstr.* 20: 499, 1994; *Soc. Neurosci. Abstr.* 21:1589, 1995; *Soc. Neurosci. Abstr.* 22:1285, 1996. We thank Eugene Orłowski for technical assistance and I. Mody for helpful comments regarding the NSAN analysis.

REFERENCES

- Abita J-P, Chicheportiche R, Schweitz H, Ladunski M. 1977. Effects of neurotoxins on (Vertradine Sea Anemone Toxin Tetrodotoxin) on transmitter accumulation and release by nerve terminal in vitro. *Biochemistry* 16:1838–1844.
- Alger B, Nicoll RA. 1982. Pharmacological evidence for two kinds of GABA receptors on rat hippocampal pyramidal cells studied in vitro. *J Physiol* 328:125–141.
- Barnes EM. 1996. Use-dependent regulation of GABA_A receptors. *Int Rev Neurobiol* 39:53–76.
- Beck SG, Birnstiel S, Pouliot W, Choi KC. 1995. Baclofen concentration-response curves differ between hippocampal subfields. *Neuroreport* 6:310–312.
- Bekkers JM, Richerson GB, Stevens CF. 1990. Origin of variability in quantal size in cultured hippocampal neurons and hippocampal slices. *Proc Natl Acad Sci* 87:5359–5362.
- Brown MJ, Bristow DR. 1996. Molecular mechanisms of benzodiazepine-induced downregulation of GABA_A receptor $\alpha 1$ subunit protein in rat cerebellar granule cells. *Br J Pharmacol* 118:1103–1110.

- Burt DR, Kamatchi GL. 1991. GABA_A receptor subtypes: From pharmacology to molecular biology. *FASEB J* 5:2916–2922.
- Chen S, Cox A, Tietz EI. 1995. Temporal regulation of GABA_A receptor (GABAR) binding and coupling in flurazepam (FZP) tolerant rats. *Soc Neurosci Abstr* 21:1590.
- Chen S, Zeng X, Sieghart W, Tietz EI. 1996. Differential changes in GABA_A receptor (GABAR) $\alpha 2$, $\beta 1$, $\beta 3$ and $\gamma 2$ subunit proteins in flurazepam tolerant rats. *Soc Neurosci Abstr* 22:1285.
- Connolly CN, Wooltorton JRA, Smart T, Moss SJ. 1996. Subcellular localization of g-aminobutyric type A receptors is determined by β subunits. *Proc Natl Acad Sci USA* 93:9899–9904.
- Davies CH, Davies SN, Collingridge GL. 1990. Paired-pulse depression of monosynaptic GABA-mediated inhibitory postsynaptic rat responses in rat hippocampus. *J Physiol (London)* 424:513–531.
- Davies PA, Hanna MC, Hales TG, Kirkness E. 1997. Insensitivity to anaesthetic agents conferred by a class of GABA_A receptor subunits. *Nature* 385:820–823.
- De Koninck Y, Mody I. 1992. Noise analysis of miniature IPSCs in adult rat brain slices: properties and modulation of synaptic GABA_A receptor channels. *J Neurophysiol* 71:1318–1335.
- Delorey TM, Olsen RW. 1992. GABA_A receptor structure and function. *J Biol Chem* 267:16747–16750.
- Ducic I, Caruncho HJ, Zhu WJ, Vicini S, Costa E. 1995. γ -Aminobutyric acid gating of Cl⁻ channels in recombinant GABA_A receptors. *J Pharmacol Exp Ther* 272:438–445.
- Edwards FA, Sakmann B. 1990. Quantal analysis of inhibitory synaptic transmission in the dentate gyrus of rat hippocampal slices: A patch-clamp study. *J Physiol* 430:213–249.
- Eghbali M, Curmi JP, Birnir B, Gage PW. 1997. Hippocampal GABA_A channel conductance increased by diazepam. *Nature* 388:71–75.
- Frerking M, Borges S, Wilson M. 1995. Variation in GABA mini amplitude is the consequence of variation in transmitter concentration. *Neuron* 15:885–895.
- Freund TF, Buzsáki G. 1996. Interneurons of the hippocampus. *Hippocampus* 6:347–470.
- Fritschy J-M, Möhler H. 1995. GABA_A-receptor heterogeneity in the adult rat brain: Differential regional and cellular distribution in seven major subunits. *J Comp Neurol* 359:154–194.
- Gallager DW, Marley RJ, Hernandez TD. 1991. Biochemical and electrophysiological mechanisms underlying benzodiazepine tolerance and dependence. In: *The biological bases of drug tolerance and dependence*. Pratt J, editor. New York: Academic Press, p 49–70.
- Gao B, Fritschy JM. 1994. Selective allocation of GABA_A receptors containing the $\alpha 1$ subunit to neurochemically distinct subpopulations of rat hippocampal interneurons. *Eur J Pharmacol* 6:837–853.
- Gingrich KJ, Roberts WA, Kass RS. 1995. Dependence of GABA_A receptor gating kinetics on the α -subunit isoform: implications for structure-function relations and synaptic transmission. *J Physiol* 489:529–543.
- Gutierrez A, Khan ZU, De Blas AL. 1994. Immunocytochemical localization of $\gamma 2$ short and $\gamma 2$ long subunits of the GABA_A receptor in the rat brain. *J Neurosci* 4:7168–7179.
- Heninger SN, Tallman JF, Garrett KM, Vitek MP, Duman RS, Gallager DW. 1990. Effects of continuous diazepam administration on GABA_A subunit mRNA in rat brain. *J Mol Neurosci* 2:101–107.
- Hajos N, Mody I. 1997. Synaptic communication among hippocampal interneurons: properties of spontaneous IPSCs in morphologically-identified cells. *J Neurosci* 17:8427–8442.
- Holt RA, Bateson AN, Martin IL. 1996. Chronic treatment with diazepam or abecarnil differently affects the expression of GABA_A receptor subunit mRNAs in the rat cortex. *Neuropharmacology* 35:1457–1463.
- Hitchcott PK, File SE, Ekwuru M, Neal MJ. 1990. Chronic diazepam treatment in rats causes long-lasting changes in central [³H]-5-hydroxytryptamine and [¹⁴C]-aminobutyric acid release. *Br J Pharmacol* 99:11–12.
- Hutchinson MA, Smith PF, Darlington CL. 1996. The behavioural and neuronal effects of the chronic administration of benzodiazepine anxiolytic and hypnotic drugs. *Prog Neurobiol* 49:73–97.
- Impagnatiello F, Pesold C, Longone P, Caruncho H, Fritschy JM, Costa E, Guidotti A. 1996. Modifications of γ -aminobutyric acid_A receptor subunit expression in rat neocortex during tolerance to diazepam. *Mol Pharmacol* 49:822–831.
- Isaacson JS, Solis JM, Nicoll RA. 1993. Local and diffuse synaptic actions of GABA in the hippocampus. *Neuron* 10:165–175.
- Itier V, Granger P, Perrault G, Depoortere H, Scatton B, Avenet P. 1996. Prolonged treatment with diazepam reduces benzodiazepine receptor-mediated potentiation of γ -aminobutyric acid-induced currents in dissociated rat hippocampal neurons. *J Pharmacol Exp Ther* 279:1092–1099.
- Jeffreys JGR, Traub RD, Whittington MA. 1996. Neuronal networks for induced '40 Hz' rhythms *Trends Neurosci* 19:202–208.
- Kang L, Miller LG. 1991. Decreased GABA_A receptor subunit mRNA concentrations following chronic lorazepam administration. *Br J Pharmacol* 103:1283–1287.
- Kapur J, Macdonald RL. 1996. Pharmacological properties of GABA_A receptors from acutely dissociated rat dentate granule cells. *Mol Pharmacol* 50:458–466.
- Klein RL, Whiting PJ, Harris RA. 1994. Benzodiazepine treatment causes uncoupling of recombinant GABA_A receptors expressed in stably transfected cells. *J Neurochem* 63:2349–2351.
- Lacaille J-C, Kunkel DD, Schwartzkroin PA. 1989. Electrophysiological and morphological characterization of hippocampal interneurons. In: *The hippocampus: new vistas*. V Chan-Palay and C Kohler, editors. New York: Alan R. Liss, p 287–305.
- Ling DSF, Bernardo LS. 1995. Activity-dependent depression of monosynaptic fast IPSCs in hippocampus: contributions from reductions in chloride driving force and conductance. *Brain Res* 670:142–146.
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent *J Biol Chem* 193:265–275.
- Lupica CR. 1995. δ and m enkephalins inhibit spontaneous GABA-mediated IPSCs via a cyclic amp-independent mechanism in the rat hippocampus. *J Neurosci*, 15:737–749.
- Macdonald, RL, Olsen, RW. 1994. GABA_A receptor channels. *Annu Rev Neurosci*, 17:569–602.
- Maconochie, DJ, Zempel, JM, Steinbach, JH. 1994. How quickly can GABA_A receptors open. *Neuron*, 12:61–71.
- Mellor JR, Randall AD. 1997. Frequency-dependent actions of benzodiazepines on GABA_A receptors in cultured murine cerebellar granule cells. *J Physiol* 503:353–369.
- Michelson HB, Wong RK.S. 1991. Excitatory synaptic responses mediated by GABA_A receptors in the hippocampus. *Science* 253:1420–1423.
- Miles R, Toth K, Gulyas AI, Hajos N, Freund TF. 1996. Differences between somatic and dendritic inhibition in the hippocampus. *Neuron*, 16:515–523.
- Moreno JI, Piva MA, Miralles CP, De Blas AL. 1994. Immunocytochemical localization of the $\beta 2$ subunit of the gamma-aminobutyric acid_A in the rat brain. *J Comp Neurol* 350:260–271.
- Mott DD, Lewis DV. 1994. The pharmacology and function of central GABA_B receptors. *Int Rev Neurobiol* 36:97–223.
- Nusser Z, Sieghart W, Benke D, Fritschy JM, Somogyi P. 1996. Differential synaptic localization of two major gamma-aminobutyric acid type A receptor alpha subunits on hippocampal pyramidal cells. *Proc Natl Acad Sci USA* 93:11939–11944.
- Nusser Z, Cull-Candy S, Farrant M. 1997. Differences in Synaptic GABA_A receptor number underlie variation in GABA mini amplitude. *Neuron* 19:697–709.
- O'Donovan MC, Buckland PR, Spurlock G, McGuffin P. 1992. Bidirectional changes in the levels of messenger RNAs encoding γ -aminobutyric acid A receptor subunits after flurazepam treatment. *Eur J Pharmacol* 226:335–341.
- Otis TS, Mody I. 1992. Modulation of decay kinetics and frequency of GABA_A receptor-mediated spontaneous hippocampal neurons. *Neuroscience* 49:13–32.
- Pearce RA, Grunder SD, Faucher LD. 1995. Different Mechanisms for use-dependent depression of two GABA_A-mediated IPSCs in rat hippocampus. *J Physiol* 484:425–435.
- Perez-Velazquez JL, Angelides KJ. 1993. Assembly of GABA_A receptor subunits determines sorting and localization in polarized cells *Nature* 361:457–460.
- Perrais D, Ropert N. 1997. Effects of zolpidem on mIPSCs and occupancy of GABA_A receptors in central synapses. *Soc Neurosci Abstr* 23:950.
- Poisbeau P, Williams SJ, Mody I. 1997. Silent GABA_A synapses during flurazepam withdrawal are region specific in the hippocampal formation. *J Neurosci* 17 3467–3475.
- Poncer JC, Durr R, Gähwiler BH, Thompson SM. 1996. Modulation of synaptic GABA_A receptor function by benzodiazepines in area CA3 of rat hippocampal slice cultures. *Neuropharmacology* 35:1169–1179.
- Primus RJ, Yu J, Xu J, Hartnett C, Meyyappan M, Kostas C, Ramabhadran TV, Gallager DW. 1996. Allosteric Uncoupling after chronic benzodiazepine exposure of recombinant γ -aminobutyric acid_A receptors expressed in Sf9 cells: Ligand efficacy and subtype selectivity. *J Pharmacol Exp Ther* 276:882–890.
- Ramsey-Williams VA, Wu Y, Rosenberg HC. 1994. Comparison of anticonvulsant tolerance, cross tolerance and benzodiazepine receptor binding following chronic treatment with diazepam or midazolam. *Pharmacol Biochem Behav* 48:765–722.
- Rogers CJ, Twyman RE, Macdonald RL. 1994. Benzodiazepine and β -carboline regulation of single GABA_A receptor channels of mouse spinal neurons in culture. *J Physiol (London)* 475:69–82.

- Ropert N, Miles R, Korn H. 1990. Characteristics of miniature inhibitory postsynaptic currents in CA1 pyramidal neurons of rat hippocampus. *J Physiol* 428:707-722.
- Rosenberg HR. 1995. Differential expression of benzodiazepine anticonvulsant cross-tolerance according to time following flurazepam or diazepam treatment. *Pharmacol Biochem Behav* 51:363-368.
- Rosenberg HC, Tietz EI, Chiu TH. 1985. Tolerance to the anticonvulsant action of benzodiazepines: Relationship to decreased receptor density. *Neuropharmacology* 24:639-644.
- Ruano D, Vizuete M, Cano J, Machado A, Vitorica J. 1992. Heterogeneity in allosteric interaction between the γ -aminobutyric acid (GABA) binding site and three different benzodiazepine binding sites of the GABA/benzodiazepine receptor complex in the rat nervous system. *J Neurochem* 58:485-493.
- Sah P, Hestrin S, Nicoll RA. 1990. Properties of excitatory postsynaptic currents recorded in vitro from rat hippocampal interneurons. *J Physiol* 430:605-616.
- Samulack DD, Williams S, Lacaille JC. 1993. Hyperpolarizing synaptic potentials evoked in CA1 pyramidal cells by glutamate stimulation of interneurons from the oriens/alveus of rat hippocampal slices. I. Electrophysiological response properties. *Hippocampus* 3:331-344.
- Schönrock B, Bormann J. 1993. Functional heterogeneity of hippocampal GABA_A receptors. *Eur J Neurosci* 5:1042-1049.
- Sieghart W. 1995. Structure and pharmacology of γ -aminobutyric acid_A receptor subtypes. *Pharmacol Rev* 47:181-234.
- Sigel E, Baur R, Trube G, Mähler H, Mahlerb P. 1990. The effect of subunit composition of rat brain GABA_A receptors on channel function. *Neuron* 5:703-711.
- Soltész I, Dechénes M. 1993. Low- and high-frequency membrane potential oscillations during theta activity in CA1 and CA3 pyramidal neurons of the rat hippocampus under ketamine-xylazine anesthesia. *J Neurophysiol* 70:97-116.
- Smith GB, Olsen RW. Functional domains of GABA_A receptors 1995. *Trends Pharmacol Sci* 16:162-168.
- Sperk G, Schwarzer C, Tsunashima K, Fuchs K, Sieghart W. 1997. GABA(A) receptor subunits in the rat hippocampus I: Immunocytochemical distribution of 13 subunits. *Neuroscience* 80:987-1000.
- Study RE, Barker JL. 1981. Diazepam and (-)-pentobarbital: fluctuation analysis reveals different mechanisms for potentiation of GABA responses in cultured central neurons. *Proc Natl Acad Sci* 78:7180-7184.
- Tietz EI, Rosenberg HC. 1988. Behavioral measurement of benzodiazepine tolerance and GABAergic subsensitivity in the substantia nigra pars reticulata. *Brain Res* 438:41-51.
- Tietz EI, Huang X, Weng X, Rosenberg HC, Chiu TH. 1994. Expression of $\alpha 1$, $\alpha 5$, and $\gamma 2$ GABA_A receptor subunit mRNAs measured in situ in rat hippocampus and cortex following chronic flurazepam administration. *J Mol Neurosci* 4:277-292.
- Tietz EI, Huang X, Chen S, Ferencak II. 1998. Temporal and regional regulation of $\alpha 1$, $\beta 2$ and $\beta 3$, but not $\alpha 2$, $\alpha 4$, $\alpha 5$, $\alpha 6$, $\beta 1$ or $\gamma 2$ GABA_A receptor subunit mRNAs following one week oral flurazepam administration. *Neuroscience* (in press).
- Verdoorn TA, Draguhn A, Ymer S, Seeburg PH, Sakmann B. 1990. Functional properties of recombinant rat GABA_A receptors depend upon subunit composition. *Neuron* 4:919-928.
- Whittington MA, Traub RD, Jeffreys JGR. 1995. Synchronized oscillations in interneuron networks driven by metabotropic glutamate receptor activation. *Nature* 373:612-615.
- Wisden W, Laurie DJ, Monyer H, Seeburg PH. 1992. The distribution of 13 GABA_A receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, and mesencephalon. *J Neurosci* 12:1040-1062.
- Xie X-H, Tietz EI. 1991. Chronic benzodiazepine treatment of rats induces reduction of paired-pulse inhibition in CA1 region of in vitro hippocampal slices. *Brain Res* 561:69-76.
- Xie X-H, Tietz EI. 1992. Reduction in potency of selective GABA_A agonists and diazepam in CA1 region of in vitro hippocampal slices from chronic flurazepam treated rats. *J Pharmacol Exp Ther* 262:204-210.
- Zeng X, Tietz EI. 1994. Impairment of feedforward inhibition in CA1 region of hippocampus after chronic benzodiazepine treatment. *Neurosci Lett* 173:40-44.
- Zeng X, Tietz EI. 1997. Depression of both early and late monosynaptic inhibitory postsynaptic potentials in hippocampal CA1 neurons following chronic benzodiazepine administration. *Synapse* 25:125-136.
- Zeng X, Xie X-H, Tietz EI. 1995. Reduction of GABA-mediated IPSPs in hippocampal CA1 pyramidal neurons following oral flurazepam administration. *Neuroscience* 66:87-99.
- Zhao T, Chiu TH, Rosenberg HC. 1994. Decreased expression of γ -aminobutyric acid Type A/benzodiazepine receptor β subunit mRNAs in flurazepam-tolerant rats. *J Mol Neurosci* 5:181-192.